Cephalon Inc. Harvard Case Solution & Analysis

In early 1997, Cephalon, waited for the FDA panel whether its drug, Myotrophin, is approved. If the drug is approved, the company may require substantial additional funding for commercialization, as well as to buy the rights to it (which were previously sold to finance its development.) CFO of considering various financing strategies, including options to purchase its own shares of the company and pay for the option by issuing shares at the moment. "Hide
by Peter Tufano, Geoffrey Verter, Markus F. Mullarkey Source: Harvard Business School 18 pages. Publication Date: April 13, 1998. Prod. #: 298116-PDF-ENG

Cephalon Inc. Case Solution Other Similar Case Solutions like

Cephalon Inc.

Share This